HomeCompareDKLRF vs PFE

DKLRF vs PFE: Dividend Comparison 2026

DKLRF yields 181818.18% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DKLRF wins by $1.8951031795759825e+29M in total portfolio value
10 years
DKLRF
DKLRF
● Live price
181818.18%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8951031795759825e+29M
Annual income
$189,305,502,041,192,720,000,000,000,000,000,000.00
Full DKLRF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DKLRF vs PFE

📍 DKLRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDKLRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DKLRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DKLRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DKLRF
Annual income on $10K today (after 15% tax)
$15,454,545.45/yr
After 10yr DRIP, annual income (after tax)
$160,909,676,735,013,800,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, DKLRF beats the other by $160,909,676,735,013,800,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DKLRF + PFE for your $10,000?

DKLRF: 50%PFE: 50%
100% PFE50/50100% DKLRF
Portfolio after 10yr
$9.475515897879912e+28M
Annual income
$94,652,751,020,596,360,000,000,000,000,000,000.00/yr
Blended yield
99.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DKLRF
No analyst data
Altman Z
-4.7
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DKLRF buys
0
PFE buys
0
No recent congressional trades found for DKLRF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDKLRFPFE
Forward yield181818.18%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.8951031795759825e+29M$51.1K
Annual income after 10y$189,305,502,041,192,720,000,000,000,000,000,000.00$27,210.54
Total dividends collected$1.8949690612486723e+29M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DKLRF vs PFE ($10,000, DRIP)

YearDKLRF PortfolioDKLRF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$18,192,518$18,181,818.18$9,161$701.38+$18.18MDKLRF
2$30,932,835,887$30,913,369,892.64$8,610$859.79+$30932.83MDKLRF
3$49,156,619,660,049$49,123,521,525,649.34$8,366$1,081.25+$49156619.65MDKLRF
4$73,009,768,971,452,110$72,957,171,388,415,860.00$8,483$1,405.66+$73009768971.44MDKLRF
5$101,348,671,691,011,770,000$101,270,551,238,212,300,000.00$9,084$1,907.24+$101348671691011.75MDKLRF
6$131,490,628,941,834,950,000,000$131,382,185,863,125,600,000,000.00$10,418$2,732.78+$131490628941834960.00MDKLRF
7$159,445,709,700,484,420,000,000,000$159,305,014,727,516,640,000,000,000.00$13,007$4,193.56+$159445709700484431872.00MDKLRF
8$180,706,560,655,892,340,000,000,000,000$180,535,953,746,512,850,000,000,000,000.00$18,010$7,005.87+$1.8070656065589233e+23MDKLRF
9$191,416,744,304,199,340,000,000,000,000,000$191,223,388,284,297,560,000,000,000,000,000.00$28,216$12,979.89+$1.9141674430419936e+26MDKLRF
10$189,510,317,957,598,240,000,000,000,000,000,000$189,305,502,041,192,720,000,000,000,000,000,000.00$51,081$27,210.54+$1.8951031795759825e+29MDKLRF

DKLRF vs PFE: Complete Analysis 2026

DKLRFStock

Decklar Resources Inc. operates as an independent international oil and gas company in Nigeria and Canada. The company explores for copper, lead, and zinc deposits. It focuses on appraisal and development in the West African region. The company holds interests in the Oza Oil Field that covers an area of 20 square kilometers located onshore in the northern part of Oil Mining Lease (OML) 11 in Nigeria's Eastern Niger Delta; the Asaramatoru Field located onshore in the southern swamp section of OML 11 in the Eastern Niger Delta; and the Emohua Oil Field located onshore in the southeastern section of OML 22 in the Eastern Niger Delta. It also holds an option to acquire a 75% interest in the Holt property that covers an area of 3,687 hectares located in east of Duncan, British Columbia. It also provides funding and technical advisory services to exploration and development companies The company was formerly known as Asian Mineral Resources Limited and changed its name to Decklar Resources Inc. in September 2020. Decklar Resources Inc. was incorporated in 2004 and is based in Toronto, Canada.

Full DKLRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DKLRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DKLRF vs SCHDDKLRF vs JEPIDKLRF vs ODKLRF vs KODKLRF vs MAINDKLRF vs JNJDKLRF vs MRKDKLRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.